455 related articles for article (PubMed ID: 17403612)
1. TRAIL signalling: decisions between life and death.
Falschlehner C; Emmerich CH; Gerlach B; Walczak H
Int J Biochem Cell Biol; 2007; 39(7-8):1462-75. PubMed ID: 17403612
[TBL] [Abstract][Full Text] [Related]
2. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract][Full Text] [Related]
3. TRAIL death receptors and cancer therapeutics.
Huang Y; Sheikh MS
Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
[TBL] [Abstract][Full Text] [Related]
4. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
[TBL] [Abstract][Full Text] [Related]
5. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.
Siegmund D; Klose S; Zhou D; Baumann B; Röder C; Kalthoff H; Wajant H; Trauzold A
Cell Signal; 2007 Jun; 19(6):1172-84. PubMed ID: 17291719
[TBL] [Abstract][Full Text] [Related]
6. TRAIL/TRAIL-R in hematologic malignancies.
Testa U
J Cell Biochem; 2010 May; 110(1):21-34. PubMed ID: 20336667
[TBL] [Abstract][Full Text] [Related]
7. The clinical trail of TRAIL.
Duiker EW; Mom CH; de Jong S; Willemse PH; Gietema JA; van der Zee AG; de Vries EG
Eur J Cancer; 2006 Sep; 42(14):2233-40. PubMed ID: 16884904
[TBL] [Abstract][Full Text] [Related]
8. TRAIL and cancer therapy.
Kruyt FA
Cancer Lett; 2008 May; 263(1):14-25. PubMed ID: 18329793
[TBL] [Abstract][Full Text] [Related]
9. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
Secchiero P; Zauli G
Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
[TBL] [Abstract][Full Text] [Related]
10. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
11. Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response.
Chen LH; Jiang CC; Kiejda KA; Wang YF; Thorne RF; Zhang XD; Hersey P
Carcinogenesis; 2007 Nov; 28(11):2328-36. PubMed ID: 17652336
[TBL] [Abstract][Full Text] [Related]
12. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
13. Role of IG20 splice variants in TRAIL resistance.
Prabhakar BS; Mulherkar N; Prasad KV
Clin Cancer Res; 2008 Jan; 14(2):347-51. PubMed ID: 18223207
[TBL] [Abstract][Full Text] [Related]
14. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
Johnstone RW; Frew AJ; Smyth MJ
Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
[TBL] [Abstract][Full Text] [Related]
15. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
16. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
17. Treatment combinations targeting apoptosis to improve immunotherapy of melanoma.
Hersey P; Zhang XD
Cancer Immunol Immunother; 2009 Nov; 58(11):1749-59. PubMed ID: 19551381
[TBL] [Abstract][Full Text] [Related]
18. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
[TBL] [Abstract][Full Text] [Related]
19. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
[TBL] [Abstract][Full Text] [Related]
20. Targeting TRAIL agonistic receptors for cancer therapy.
Carlo-Stella C; Lavazza C; Locatelli A; Viganò L; Gianni AM; Gianni L
Clin Cancer Res; 2007 Apr; 13(8):2313-7. PubMed ID: 17438088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
